Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

High seroprevalence again… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

High seroprevalence against hepatitis E virus in patients with chronic hepatitis C virus infection

Artikel i vetenskaplig tidskrift
Författare A. Mellgren
M. Karlsson
Marie Karlsson
Martin Lagging
Rune Wejstål
Helene Norder
Publicerad i Journal of Clinical Virology
Volym 88
Sidor 39-45
ISSN 1386-6532
Publiceringsår 2017
Publicerad vid Institutionen för biomedicin, avdelningen för infektionssjukdomar
Sidor 39-45
Språk en
Länkar https://doi.org/10.1016/j.jcv.2017....
Ämnesord Chronic liver disease, HCV, HEV, chronic liver-disease, united-states, high prevalence, antibodies, blood, epidemiology, countries, sweden, decompensation, superinfection, Virology
Ämneskategorier Epidemiologi, Virologi, Infektionsmedicin

Sammanfattning

Background: Hepatitis E virus (HEV) genotype 3 is endemic in Europe. Superinfection with HEV in patients with underlying chronic liver disease can cause hepatic decompensation leading to increased morbidity and mortality. Objectives: The prevalence of anti-HEV antibodies was investigated in 204 patients with chronic hepatitis C virus (HCV) infection and different stages of fibrosis. Results: The median age of the patients was 55 years (IQR 40-62 years); 126 (62%) were men. Ninety-eight (48%) patients had a METAVIR fibrosis stage F2 or higher. The prevalence of anti-HEV IgG was 30% (62/204), which was significantly higher than among Swedish blood donors (17%, p < 0.01). The prevalence of anti-HEV antibodies was associated with higher age (OR 1.08 (1.05-1.11); p < 0.01). It was also higher for patients with a prior history of blood transfusion (48%) as compared to intravenous drug use (IDU; 26%) as the risk factor for acquisition of the HCV infection (OR 2.72 (1.2-6.19); p <0.02). The prevalence of anti-HEV IgG was also significantly higher in patients with significant fibrosis, i.e. >= F2 (38%; OR 2.04 (1.11-3.76); p = 0.02) and/or neoplasm (72%; OR 7.27 (2.46-21.44); p < 0.01). Conclusions: When adjusted for age, the prevalence of anti-HEV antibodies was significantly higher in patients with previous or current malignant liver disease compared to blood donors. The lack of significant correlation between HCV and HEV infections indicate low level of transmission of HEV by IDU. HEV infections warrant more attention, especially in patients with preexisting liver disease. (C) 2017 The Author(s). Published by Elsevier B.V.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?